305 related articles for article (PubMed ID: 28264701)
1. Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells.
Ubellacker JM; Haider MT; DeCristo MJ; Allocca G; Brown NJ; Silver DP; Holen I; McAllister SS
Breast Cancer Res; 2017 Mar; 19(1):23. PubMed ID: 28264701
[TBL] [Abstract][Full Text] [Related]
2. Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo.
Ottewell PD; Wang N; Brown HK; Reeves KJ; Fowles CA; Croucher PI; Eaton CL; Holen I
Clin Cancer Res; 2014 Jun; 20(11):2922-32. PubMed ID: 24687923
[TBL] [Abstract][Full Text] [Related]
3. Modifying the osteoblastic niche with zoledronic acid in vivo-potential implications for breast cancer bone metastasis.
Haider MT; Holen I; Dear TN; Hunter K; Brown HK
Bone; 2014 Sep; 66(100):240-50. PubMed ID: 24971713
[TBL] [Abstract][Full Text] [Related]
4. Oestrogen receptor positive breast cancer metastasis to bone: inhibition by targeting the bone microenvironment in vivo.
Holen I; Walker M; Nutter F; Fowles A; Evans CA; Eaton CL; Ottewell PD
Clin Exp Metastasis; 2016 Mar; 33(3):211-24. PubMed ID: 26585891
[TBL] [Abstract][Full Text] [Related]
5. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.
Ottewell PD; Mönkkönen H; Jones M; Lefley DV; Coleman RE; Holen I
J Natl Cancer Inst; 2008 Aug; 100(16):1167-78. PubMed ID: 18695136
[TBL] [Abstract][Full Text] [Related]
6. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model.
Hiraga T; Williams PJ; Ueda A; Tamura D; Yoneda T
Clin Cancer Res; 2004 Jul; 10(13):4559-67. PubMed ID: 15240548
[TBL] [Abstract][Full Text] [Related]
7. The effects of zoledronic acid in the bone and vasculature support of hematopoietic stem cell niches.
Soki FN; Li X; Berry J; Koh A; Sinder BP; Qian X; Kozloff KM; Taichman RS; McCauley LK
J Cell Biochem; 2013 Jan; 114(1):67-78. PubMed ID: 22833499
[TBL] [Abstract][Full Text] [Related]
8. Zoledronic Acid Inhibits the Motility of Cancer Stem-like Cells from the Human Breast Cancer Cell Line MDA-MB 231.
Bühler H; Hoberg C; Fakhrian K; Adamietz IA
In Vivo; 2016 11-12; 30(6):761-768. PubMed ID: 27815459
[TBL] [Abstract][Full Text] [Related]
9. Preclinical evaluation of zoledronate using an in vitro mimetic cellular model for breast cancer metastatic bone disease.
Dedes PG; Kanakis I; Gialeli Ch; Theocharis AD; Tsegenidis T; Kletsas D; Tzanakakis GN; Karamanos NK
Biochim Biophys Acta; 2013 Jun; 1830(6):3625-34. PubMed ID: 23395844
[TBL] [Abstract][Full Text] [Related]
10. Functional inhibition of osteoblastic cells in an in vivo mouse model of myeloid leukemia.
Frisch BJ; Ashton JM; Xing L; Becker MW; Jordan CT; Calvi LM
Blood; 2012 Jan; 119(2):540-50. PubMed ID: 21957195
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the in vitro and in vivo antiangiogenic effects of denosumab and zoledronic acid.
Misso G; Porru M; Stoppacciaro A; Castellano M; De Cicco F; Leonetti C; Santini D; Caraglia M
Cancer Biol Ther; 2012 Dec; 13(14):1491-500. PubMed ID: 22990205
[TBL] [Abstract][Full Text] [Related]
12. The combined use of Camellia sinensis and metronomic zoledronic acid in a breast cancer-induced osteolysis mouse model.
Luo KW; Ko CH; Yue GG; Gao S; Lee JK; Li G; Fung KP; Leung PC; Evdokiou A; Lau CB
J Cancer Res Clin Oncol; 2015 Jun; 141(6):1025-36. PubMed ID: 25431338
[TBL] [Abstract][Full Text] [Related]
13. Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model.
Labrinidis A; Hay S; Liapis V; Ponomarev V; Findlay DM; Evdokiou A
Clin Cancer Res; 2009 May; 15(10):3451-61. PubMed ID: 19401351
[TBL] [Abstract][Full Text] [Related]
14. Modulating Bone Marrow Hematopoietic Lineage Potential to Prevent Bone Metastasis in Breast Cancer.
Ubellacker JM; Baryawno N; Severe N; DeCristo MJ; Sceneay J; Hutchinson JN; Haider MT; Rhee CS; Qin Y; Gregory WM; Garrido-Castro AC; Holen I; Brown JE; Coleman RE; Scadden DT; McAllister SS
Cancer Res; 2018 Sep; 78(18):5300-5314. PubMed ID: 30065048
[TBL] [Abstract][Full Text] [Related]
15. Cocultures of osteoblasts and osteoclasts are influenced by local application of zoledronic acid incorporated in a poly(D,L-lactide) implant coating.
Greiner S; Kadow-Romacker A; Schmidmaier G; Wildemann B
J Biomed Mater Res A; 2009 Oct; 91(1):288-95. PubMed ID: 18980195
[TBL] [Abstract][Full Text] [Related]
16. Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo.
Wright LE; Harhash AA; Kozlow WM; Waning DL; Regan JN; She Y; John SK; Murthy S; Niewolna M; Marks AR; Mohammad KS; Guise TA
Oncotarget; 2017 Jan; 8(5):8406-8419. PubMed ID: 28039445
[TBL] [Abstract][Full Text] [Related]
17. Macrophages as potential targets for zoledronic acid outside the skeleton-evidence from in vitro and in vivo models.
Rogers TL; Wind N; Hughes R; Nutter F; Brown HK; Vasiliadou I; Ottewell PD; Holen I
Cell Oncol (Dordr); 2013 Dec; 36(6):505-14. PubMed ID: 24177992
[TBL] [Abstract][Full Text] [Related]
18. Osteoclast activity modulates B-cell development in the bone marrow.
Mansour A; Anginot A; Mancini SJ; Schiff C; Carle GF; Wakkach A; Blin-Wakkach C
Cell Res; 2011 Jul; 21(7):1102-15. PubMed ID: 21321604
[TBL] [Abstract][Full Text] [Related]
19. Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial.
Banys M; Solomayer EF; Gebauer G; Janni W; Krawczyk N; Lueck HJ; Becker S; Huober J; Kraemer B; Wackwitz B; Hirnle P; Wallwiener D; Fehm T
BMC Cancer; 2013 Oct; 13():480. PubMed ID: 24128322
[TBL] [Abstract][Full Text] [Related]
20. Zoledronic acid sensitizes breast cancer cells to fulvestrant via ERK/HIF-1 pathway inhibition in vivo.
Jia X; Cheng J; Shen Z; Shao Z; Liu G
Mol Med Rep; 2018 Apr; 17(4):5470-5476. PubMed ID: 29393454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]